These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37419502)

  • 1. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis.
    Relan P; Motaze NV; Kothari K; Askie L; Le Polain O; Van Kerkhove MD; Diaz J; Tirupakuzhi Vijayaraghavan BK
    BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37419502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes.
    Mondi A; Mastrorosa I; Piselli P; Cimaglia C; Matusali G; Carletti F; Giannico G; Milozzi E; Biliotti E; Di Bari S; Chinello P; Beccacece A; Faraglia F; Vittozzi P; Mosti S; Tetaj N; Stazi GV; Pinnetti C; Camici M; D'Annunzio A; Marani A; Fabeni L; Specchiarello E; Gruber CEM; Villanacci A; Minicucci S; Garbuglia AR; Ianniello S; Marchioni L; Taglietti F; D'Offizi G; Palmieri F; Nicastri E; Maggi F; Vaia F; Girardi E; Antinori A
    J Med Virol; 2023 Jun; 95(6):e28831. PubMed ID: 37246793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.
    Ward T; Glaser A; Overton CE; Carpenter B; Gent N; Seale AC
    Epidemiol Infect; 2022 Dec; 151():e32. PubMed ID: 36535802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection.
    Sočan M; Mrzel M; Prosenc K; Korva M; Avšič-Županc T; Poljak M; Lunar MM; Zupanič T
    Front Public Health; 2024; 12():1294261. PubMed ID: 38450129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
    Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
    JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients.
    Hu FH; Jia YJ; Zhao DY; Fu XL; Zhang WQ; Tang W; Hu SQ; Wu H; Ge MW; Du W; Shen WQ; Zhu B; Chen HL
    Clin Microbiol Infect; 2023 Jul; 29(7):835-844. PubMed ID: 36934872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
    J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.
    COVID-19 Forecasting Team
    Lancet; 2023 Mar; 401(10379):833-842. PubMed ID: 36930674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.
    Xia H; Yeung J; Kalveram B; Bills CJ; Chen JY; Kurhade C; Zou J; Widen SG; Mann BR; Kondor R; Davis CT; Zhou B; Wentworth DE; Xie X; Shi PY
    Emerg Microbes Infect; 2023 Dec; 12(1):e2161422. PubMed ID: 36594261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19.
    de Prost N; Audureau E; Heming N; Gault E; Pham T; Chaghouri A; de Montmollin N; Voiriot G; Morand-Joubert L; Joseph A; Chaix ML; Préau S; Favory R; Guigon A; Luyt CE; Burrel S; Mayaux J; Marot S; Roux D; Descamps D; Meireles S; Pène F; Rozenberg F; Contou D; Henry A; Gaudry S; Brichler S; Timsit JF; Kimmoun A; Hartard C; Jandeaux LM; Fafi-Kremer S; Gabarre P; Emery M; Garcia-Sanchez C; Jochmans S; Pitsch A; Annane D; Azoulay E; Mekontso Dessap A; Rodriguez C; Pawlotsky JM; Fourati S
    Nat Commun; 2022 Oct; 13(1):6025. PubMed ID: 36224216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.
    Lewnard JA; Hong VX; Patel MM; Kahn R; Lipsitch M; Tartof SY
    Nat Med; 2022 Sep; 28(9):1933-1943. PubMed ID: 35675841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent.
    Pascall DJ; Vink E; Blacow R; Bulteel N; Campbell A; Campbell R; Clifford S; Davis C; da Silva Filipe A; El Sakka N; Fjodorova L; Forrest R; Goldstein E; Gunson R; Haughney J; Holden MTG; Honour P; Hughes J; James E; Lewis T; MacLean O; McHugh M; Mollett G; Nyberg T; Onishi Y; Parcell B; Ray S; Robertson DL; Seaman SR; Shabaan S; Shepherd JG; Smollett K; Templeton K; Wastnedge E; Wilkie C; Williams T; ; Thomson EC
    J Infect; 2023 Aug; 87(2):128-135. PubMed ID: 37270070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021.
    Vauhkonen H; Nguyen PT; Kant R; Plyusnin I; Erdin M; Kurkela S; Liimatainen H; Ikonen N; Blomqvist S; Liitsola K; Lindh E; Helve O; Jarva H; Loginov R; Palva A; Hannunen T; Hannula S; Parry M; Kauppi P; Vaheri A; Sironen T; Lappalainen M; Savolainen-Kopra C; Smura T; Vapalahti O
    Emerg Infect Dis; 2022 Jun; 28(6):1229-1232. PubMed ID: 35378057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variants BA.2, BA.5 and BQ.1.1 in critically ill patients with COVID-19: a prospective, multicenter cohort study.
    de Prost N; Audureau E; Préau S; Favory R; Guigon A; Bay P; Heming N; Gault E; Pham T; Chaghouri A; Voiriot G; Morand-Joubert L; Jochmans S; Pitsch A; Meireles S; Contou D; Henry A; Joseph A; Chaix ML; Uhel F; Descamps D; Emery M; Garcia-Sanchez C; Luyt CE; Marot S; Pène F; Lhonneur AS; Gaudry S; Brichler S; Picard L; Mekontso Dessap A; Rodriguez C; Pawlotsky JM; Fourati S;
    Intensive Care Med Exp; 2023 Aug; 11(1):48. PubMed ID: 37544942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review.
    Arabi M; Al-Najjar Y; Mhaimeed N; Salameh MA; Paul P; AlAnni J; Abdelati AA; Laswi I; Khanjar B; Al-Ali D; Elshafeey A; Mhaimeed O; Burney Z; D'Souza A; Sinha P; Bhatti M; Pillai KV; Homssi M; Bshesh K; Yagan L; Zakaria D
    J Cell Mol Med; 2023 Jun; 27(11):1443-1464. PubMed ID: 37203288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severity outcomes of SARS-CoV-2 infection in the Omicron and pre-Omicron periods, in unvaccinated first-time test positive adults less than 65 years old without comorbidity, in Sweden.
    Wahlström E; Bruce D; Bennet-Bark AM; Walther S; Hanberger H; Strålin K
    J Infect Public Health; 2024 Sep; 17(9):102502. PubMed ID: 39059030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.
    Shuai H; Chan JF; Hu B; Chai Y; Yoon C; Liu H; Liu Y; Shi J; Zhu T; Hu JC; Hu YF; Hou Y; Huang X; Yuen TT; Wang Y; Zhang J; Xia Y; Chen LL; Cai JP; Zhang AJ; Yuan S; Zhou J; Zhang BZ; Huang JD; Yuen KY; To KK; Chu H
    EBioMedicine; 2023 Sep; 95():104753. PubMed ID: 37579626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.